

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

U.S. PATENT DOCUMENTS

| Examiner | Cite No. ¹ | Document Number Number Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------------|---|--------------------------------|--|---|
| | 1153 | 2006/0234912 | 10-16-2006 | Wang et al. | |
| | 1154 | 2006/0182321 | 08-17-2006 | Hu et al. | |
| | 1155 | 2006/0121038 | 06-08-2006 | Schenk et al. | |
| | 1160 | 5,472,693 | 12-05-1995 | Gourlie et al. | |
| | 1168 | 5,620,844 | 04-15-1997 | Neurath et al. | |
| | 1169 | 2009/0142270 A1 | 06-04-2009 | Schroeter et al. | |
| | 1170 | 2003/0009104 A1 | 01-09-2003 | Hyman et al. | |
| | 1192 | 7,582,733 | 09-01-2009 | Basi et al. | |
| | 1195 | 6,824,780 B1 | 11-30-2004 | Devaux et al. | |
| | 1196 | 7,147,851 B1 | 12-12-2006 | Ponath et al. | |
| | 1197 | 7,112,661 B1 | 09-26-2006 | Miller | |
| | 1209 | 5,910,427 | 06-08-1999 | Mikayama | |
| | 1210 | 2007/0072307 A1 | 03-29-2007 | Godavarti et al. | |
| | 1211 | 6,432,710 B1 | 08-13-2002 | Boss, Jr. et al. | |
| | 1215 | 2009/0297511 | 12-03-2009 | Schenk | |
| | 1216 | 2009/0155256 | 6-18-2009 | Black et al. | |
| | 1242 | 5,417,986 | 05-23-1995 | Reid et al. | |
| | 1277 | 2007/0196375 | 08-23-2007 | Tobinick | |
| | 1278 | 2006/019850 | 08-31-2006 | Warne et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | 1 ⁶ |
|-----------------------|--------------------------|------------------------------|---------------------|--------------------------------------|------------------------------------|---|---|----------------|
| | | Country Code ² | Number ³ | Kind Code ² (if known) | | | | |
| | 1151 | WO | 96/39834 | A1 | 12-19-1996 | | | |
| | 1152 | WO | 01/78777 | A2 | 10-25-2001 | | | |
| | 1173 | WO | 97/18855 | A1 | 05-29-1997 | | | |
| | 1174 | WO | 90/14840 | A1 | 12-13-1990 | | | |
| | 1175 | EP | 613007 | A2 | 02-18-1994 | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

Sheet 2 of 8

| | | | | | | |
|------|----|-----------|----|------------|--|--|
| 1176 | EP | 616 814 | A1 | 03-21-1994 | | |
| 1177 | WO | 97/40147 | A1 | 10-30-1997 | | |
| 1178 | WO | 97/37031 | A1 | 10/09/1997 | | |
| 1179 | WO | 97/36601 | A1 | 10/09/1997 | | |
| 1180 | WO | 97/28816 | A1 | 08-14-1997 | | |
| 1181 | WO | 96/29421 | A1 | 09-26-1996 | | |
| 1182 | WO | 96/14061 | A1 | 05-17-1996 | | |
| 1183 | WO | 94/21288 | A1 | 09-29-1994 | | |
| 1184 | WO | 94/16731 | A1 | 08-04-1994 | | |
| 1185 | WO | 94/09823 | A1 | 05-11-1994 | | |
| 1186 | WO | 92/15330 | A1 | 09-17-1992 | | |
| 1187 | WO | 92/07944 | A1 | 05-14-1992 | | |
| 1188 | WO | 92/05793 | A1 | 04-16-1992 | | |
| 1189 | WO | 90/14837 | A1 | 12-13-1990 | | |
| 1190 | WO | 87/06838 | A1 | 11-19-1987 | | |
| 1206 | WO | 04/016282 | A1 | 2-26-2004 | | |
| 1220 | WO | 96/01126 | A1 | 01-18-1996 | | |
| 1221 | WO | 90/07861 | | 07-26-1990 | | |
| 1222 | EP | 1 185 298 | B1 | 06-24-2009 | | |
| 1223 | WO | 06/066171 | A1 | 06-22-2006 | | |
| 1224 | WO | 06/066049 | A2 | 06-22-2006 | | |
| 1225 | WO | 95/05849 | A1 | 03-02-1995 | | |
| 1227 | WO | 94/03208 | A1 | 02-17-1994 | | |
| 1228 | WO | 94/29459 | A1 | 12-22-1994 | | |
| 1236 | WO | 98/08098 | A1 | 02-26-1998 | | |
| 1237 | WO | 96/22373 | A1 | 07-25-1996 | | |
| 1238 | WO | 97/05164 | A1 | 02-13-1997 | | |
| 1239 | WO | 90/05142 | A1 | 05-17-1990 | | |
| 1240 | WO | 96/03144 | A1 | 02-08-1996 | | |
| 1244 | WO | 94/17197 | A1 | 08-04-1994 | | |
| 1249 | WO | 96/33739 | A1 | 10-31-1996 | | |
| 1250 | WO | 91/19795 | A1 | 12-26-1991 | | |
| 1251 | WO | 92/19267 | A1 | 11-12-1992 | | |
| 1257 | WO | 91/10741 | A1 | 07-25-1991 | | |
| 1258 | WO | 93/12227 | A1 | 06-24-1993 | | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

62731308 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

Sheet 3 of 8

| | | | | | | | |
|------|----|-----------|----|------------|--|--|--|
| 1259 | WO | 94/40895 | A1 | 12-19-1996 | | | |
| 1267 | WO | 98/39303 | A1 | 09-11-1998 | | | |
| 1270 | WO | 92/01059 | A1 | 01-23-1992 | | | |
| 1271 | WO | 10/044803 | A1 | 04-22-2010 | | | |
| 1274 | WO | 98/04720 | A1 | 02-05-1998 | | | |
| 1276 | WO | 09/052439 | A2 | 04-23-2009 | | | |
| 1285 | WO | 97/13855 | | 04-17-1997 | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | 1156 | ALLEN et al., "Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer," Arch. Neurol., 63(10): 1475-1478 (2006), abstract only. | |
| | 1157 | MAVRAGANI et al., "A Case of Reversible Posterior Leukoencephalopathy Syndrome After Rityximab Infusion," Rheumatology, 43(11) 1450-1451 (2006). | |
| | 1158 | PCT Written Opinion of 12/22/2008 for application PCT/US2008/80370. | |
| | 1159 | PCT Search Report of 01/22/2009 for application PCT/US2008/80370. | |
| | 1161 | Wikipedia entry for Antibody, retrieved April 27, 2009 from http://en.wikipedia.org/wiki/Antibody . | |
| | 1162 | TRANG et al., "Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1A) in Metastatic Adenocarcinoma Patients," Pharmaceutical Research 7(6):587-592 (1990). | |
| | 1163 | Genbank Accession number AAA69734, Schroeder et al., "Immunoglobulin heavy chain [Homo sapiens], Anti-DNA immunoglobulin light chain IgG [Mus musculus], 07/11/95. | |
| | 1164 | Genbank Accession number BAC01733, Akahori et al., "Immunoglobulin kappa light chain VLJ region [Homo sapiens], 07/02/02. | |
| | 1165 | SCHROEDER et al., "Preferential Utilization of Conserved Immunoglobulin Heavy Chain Variable Gene Segments During Human Fetal Life," Immunology, 87:6146-6150 (1990). | |
| | 1167 | PADLAN et al., "Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL-10 Fab-lysozyme Complex, Immunology, 86:5938-5942 (1989). | |
| | 1171 | PANGALOS et al., "Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of β -amyloid Peptide," Biochemical Society Transactions, 33(4):553-558 (2005). | |
| | 1172 | PRADA et al., "Antibody-Mediated Clearance of Amyloid- β Peptide From Cerebral Amyloid Angiopathy Revealed by quantitative in Vivo Imaging," Journal of Neuroscience, 27(8):1973-1980 (2007). | |
| | 1191 | BIEWENGA et al., "Cleavage of Protein A-binding IgA1 with IgA1 Protease From Streptococcus Sanguls," Immunol Commun., 12(5):491-500 (1983), abstract only. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

| | | |
|------|--|--|
| 1193 | HOGARTH, Fc Receptors Are Major Mediators of Antibody Based Inflammation in Autoimmunity," <u>Current Opinion in Immunology</u> , 14:798-802 (2002). | |
| 1194 | Ecuadorian Search Report of 07/02/2009 for Ecuador Patent Application No. SP 03-4685. | |
| 1198 | MITCHELL et al., "Prevention of Intracerebral Hemorrhage," <u>Current Drug Targets</u> , 8(7):832-838 (2007). | |
| 1199 | RIECHMANN et al., "Reshaping Human Antibodies for Therapy," <u>Nature</u> , 332:323-327 (1988). | |
| 1200 | HILLEN-MASKE et al., "Konichalci," <u>Rompp Chemie Lexikon</u> , 9 th edition, pg. 2322 (1990). | |
| 1201 | MUTSCHLER et al., "Arzneimittel-Wirkungen, Lehrbuch der Pharmakologie und Toxikologie," Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 6 th edition, pgs. 651-656 (1991), (German Article). | |
| 1202 | SAIDO et al., "Autolytic Transition of μ -Calpain Upon Activation as Resolved by Antibodies Distinguishing Between the Pre- and Post-Autolysis Forms," <u>J. Biochem.</u> , 111:81-86 (1992). | |
| 1203 | SOOD et al., "Synthetic Peptides: A Modern Approach to Vaccination," <u>Indian Journal of Experimental Biology</u> , 34:849-861 (1998). | |
| 1204 | BUTTINI et al., " β -Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease," <u>The Journal of Neuroscience</u> , 25(40):9096-9101 (2005). | |
| 1205 | GOLDING et al., "Vaccine Strategies: Targeting Helper T Cell Responses," <u>Annals New York Academy of Sciences</u> , 31:126-137 (1995). | |
| 1207 | BORRAS-CUESTA et al., "Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells," <u>Eur. J. Immunol.</u> , 17:1213-1215 (1987) | |
| 1208 | GHEITIE et al., "CD4 Peptide-Protein Conjugates, But Not Recombinant Human CD4, Bind to Recombinant gp120 From the Human Immunodeficiency Virus in the Presence of Serum From AIDS Patients," <u>Proc. Natl. Acad. Sci.</u> , 88:5690-5693 (1991). | |
| 1213 | PCT Search Report of 10/09/2008 for application PCT/US2008/060926. | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6

of

8

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

| | | |
|------|---|--|
| 1214 | PCT International Preliminary Report on Patentability (Chapter I) of 10/20/2009 with Written Opinion of 10/03/2008 for application PCT/US2008/060926. | |
| 1217 | PCT International Preliminary Report on Patentability (Chapter I) of 02/02/2010 for application PCT/US07/09499. | |
| 1218 | AUCLAIR et al., "Effect of Active Immunization Against Oestradiol in Developing Ram Lambs on Plasma Gonadotrophin and Testosterone Concentrations, Time of Onset of Puberty and Testicular Blood Flow," <u>Journal of Reproduction and Fertility</u> , 104:7-16 (1995). | |
| 1219 | BLACK et al., "A Single Ascending Dose Study of Banezumab, A Humanized Monoclonal Antibody to A β , In AD," <u>9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy</u> , 1 page (April 20, 2006). Abstract only. | |
| 1226 | JANEWAY et al., <u>Immunobiology</u> , 3 rd edition, pages 2:7, 2:9, 2:12, 8:16-8:17, 12:43 (1997). | |
| 1229 | BARELLI et al., "Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid β Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer's Disease and Cerebral Amyloid Angiopathy Cases," <u>Molecular Medicine</u> , 3(10):695-707 (1997). | |
| 1230 | HELLMAN et al., "Allergy Vaccines – A Review of Developments," <u>Clin. Immunother.</u> , 6(2): 130-142 (Aug. 1996). | |
| 1231 | KARDANA et al., "Serum HCG β -Core Fragment is Masked by Associated Macromolecules," <u>Journal of Clinical Endocrinology and Metabolism</u> , 71(5):1393-1395. | |
| 1232 | KOLLER et al., "Active Immunization of Mice with a A β -Hsp70 Vaccine," <u>Neurodegenerative Diseases</u> , 1:20-28 (2004). | |
| 1233 | CHECK, "Nerve Inflammation Halts Trail for Alzheimer's Drugs," <u>Nature</u> , 415:462 (2002) | |
| 1234 | GAUTHIER et al., "Alzheimer's Disease: Current Knowledge, Management and Research," <u>Can. Med. Assoc. J.</u> , "157:1047-1052 (October 15, 1997). | |
| 1235 | HUANG et al., "Amyloid β -Peptide Possesses a Transforming Growth Factor- β Activity," <u>The Journal of Biological Chemistry</u> , 273(42):27640-27644 (October 16, 1998). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 8

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

| | | |
|------|---|--|
| 1241 | TAHTINEN et al., "Minimal Size of HIV-1 NEF ANTIGENIC EPITOPES RECONIZED BY HUMAN SERA," Int. Conf. AIDS June 16-21 1991, Published June 1991, abstract no. W.A. 1334. | |
| 1243 | JARRETT et al., "The Carboxy Terminus of the β Amyloid Protein is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease," <i>Biochemistry</i> , 32:4693-4697 (November 05, 1993). | |
| 1245 | WELLING et al., "Choice of Peptide and Peptide Length For the Generation of Antibodies Reactive With the Intact Protein," <i>FEBS Letters</i> , 182(1):81-84 (March 1985). | |
| 1246 | AGADJANYAN et al., "Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope From (beta)-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide," <i>J. Immunol.</i> , 174:1580-1586 (2005). | |
| 1247 | NOVARTIS, "Novartis MF59 TM -Adjuvanted Influenza Vaccine (Fluad [®]) Significantly Reduces Hospitalization in Elderly," Novartis Press Release, October 19 2007. | |
| 1248 | DONNELLY, "New Developments in Adjuvants," <i>Mechanism of Ageing and Development</i> , 93:171-177 (1997). | |
| 1252 | JENNINGS, "Review of Selected Adjuvants Used in Antibody Production," <i>ILAR Journal</i> , 37(3) (1995). | |
| 1253 | BANDLOW et al., "Untersuchungen Zum Mechanismus Der Immunologischen Adjvanswirung des Vacciniavirus," <i>Archiv für die gesamte Virusforschung</i> , 38:192-204 (1972). German article. | |
| 1254 | KHAN et al., "Immunopotential and Delivery Systems for Antigens for Single-Step Immunization: Recent Trends and Progress," <i>Pharmaceutical Research</i> , 11(1):2-11 (1994). | |
| 1255 | HAMILTON, "Molecular Engineering: Applications to the Clinical Laboratory," <i>Clin. Chem.</i> 39(9):1988-1997 (1993). | |
| 1256 | SHEEHAN et al., "The Utilization of Individual V _H Exons in the Primary Repertoire of Adult BALB/c Mice," <i>The Journal of Immunology</i> , 151(10):5364-5375 (November 15, 1993). | |
| 1260 | HERMANSON et al., "Amino Acids as Spacers," <i>Immobilized Affinity Ligand Techniques</i> , section 3.1.1.5:150-152 (1992). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

62731308 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 8

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk |
| Art Unit | 1649 |
| Examiner Name | Kolker |
| Attorney Docket Number | 15270J-004740US |

| | | |
|------|--|--|
| 1261 | HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 139-195 (1988). | |
| 1262 | HUDSON et al., "Antibody as a Probe," <i>Practical Immunology</i> , Chapter 2, pages 34-85 (1989). | |
| 1263 | BEGLEY, "Delivery of Therapeutic Agents to the Central Nervous System: The Problems and the Possibilities," <i>Pharmacol. Therapy</i> , 104(1): 29-45 (Oct. 2004). | |
| 1264 | MISRA et al., "Drug Delivery to the Central Nervous System: A review," <i>J. Pharm Pharm Sci.</i> , 6(2):252-273 (May 2003). Abstract. | |
| 1265 | KALLBERG et al., "Prediction of Amyloid Fibril-Forming Proteins," <i>The Journal of Biological Chemistry</i> , 276(16):12945-12950 (April 20, 2001). | |
| 1268 | Genbank Accession number AAB35009.1, Wang et al., "Antidiotypic Ig 1F7 Light Chain Variable Region [Human, 1F7 Hybridoma Cells, Peptide Partial, 120aa]," 10/28/1995. | |
| 1269 | Genbank Accession number AAD00856.1, "IgM Heavy Chain Variable Region [Homo Sapiens]" 07/31/2001. | |
| 1272 | SAIDO et al., "Amino-and-Carboxyl-Terminal Heterogeneity of β -Amyloid Peptides Deposited in Human Brain," <i>Neuroscience Letters</i> , 215:173-176 (August 8, 1996). | |
| 1273 | <i>Stedman's Medical Dictionary</i> , 27 th Edition, "Vaccine," page 1922, lines 1-3 (2000). | |
| 1279 | KINNECOM et al., "Course of Cerebral Amyloid Angiopathy? Related Inflation," <i>Neurology</i> , 68(17):1411-1416 (2007). | |
| 1280 | KOFKE et al., "Remifentanyl-Induced Cerebral Blood Flow Effects in Normal Humans: Dose and ApoE genotype," <i>Neurosurg Anesthes Neurosci.</i> , 105(1):167-175 (2007). | |
| 1281 | PCT Written Opinion of 03/08/2009 for application PCT/US2008/80382. | |
| 1282 | PCT Search Report of 03/25/2009 for application PCT/US2008/80382. | |
| 1283 | AYLWARD et al., "Cerebellar Volume in Adults With Down Syndrome," <i>Arch Neurol.</i> , 4(2):209-212 (1997). Abstract only. | |
| 1284 | HOLM et al., "Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1," <i>Mol. Immunol.</i> , 44(6):1075-1084 (Feb 2007). | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

62731308 v1